AU2001265714A1 - Marker for neurodegenerative diseases and its use for drug screening targeted against said diseases - Google Patents
Marker for neurodegenerative diseases and its use for drug screening targeted against said diseasesInfo
- Publication number
- AU2001265714A1 AU2001265714A1 AU2001265714A AU6571401A AU2001265714A1 AU 2001265714 A1 AU2001265714 A1 AU 2001265714A1 AU 2001265714 A AU2001265714 A AU 2001265714A AU 6571401 A AU6571401 A AU 6571401A AU 2001265714 A1 AU2001265714 A1 AU 2001265714A1
- Authority
- AU
- Australia
- Prior art keywords
- diseases
- marker
- drug screening
- targeted against
- screening targeted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000007877 drug screening Methods 0.000 title 1
- 239000003550 marker Substances 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21141200P | 2000-06-14 | 2000-06-14 | |
| US60211412 | 2000-06-14 | ||
| PCT/BE2001/000100 WO2001096878A2 (en) | 2000-06-14 | 2001-06-14 | Marker for neurodegerative diseases and its use in drug screening |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001265714A1 true AU2001265714A1 (en) | 2001-12-24 |
Family
ID=22786822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001265714A Abandoned AU2001265714A1 (en) | 2000-06-14 | 2001-06-14 | Marker for neurodegenerative diseases and its use for drug screening targeted against said diseases |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2001265714A1 (en) |
| WO (1) | WO2001096878A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009109862A2 (en) * | 2008-03-06 | 2009-09-11 | Rolf Lewensohn | Improved cancer therapeutics |
| EP2418491A1 (en) * | 2010-08-10 | 2012-02-15 | Bioftalmik, S.L. | Method for the diagnosis of dry eye and blepharitis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9602677D0 (en) * | 1996-07-05 | 1996-07-05 | Sangtec Medical Ab | Methods for determining brain antigens |
| DE19707230C2 (en) * | 1997-02-24 | 2000-01-13 | Markus Otto | Method for recognizing a disease of an organism from transmissible spongiform encephalopathy |
-
2001
- 2001-06-14 WO PCT/BE2001/000100 patent/WO2001096878A2/en not_active Ceased
- 2001-06-14 AU AU2001265714A patent/AU2001265714A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001096878A2 (en) | 2001-12-20 |
| WO2001096878A3 (en) | 2002-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002213357A1 (en) | Variant igg3 rituxan r and therapeutic use thereof | |
| AU2001269529A1 (en) | Medicine comprising dicyanopyridine derivative | |
| IL139975A0 (en) | Anti proliferative drugs | |
| AU7815000A (en) | Targeted drug activation | |
| AU2001253020A1 (en) | Screening markers and methods for neurodegenerative disorders | |
| AU2003235956A1 (en) | Quinazoline derivative and medicine | |
| AU2001271841A1 (en) | Methods for identifying combinations of drugs | |
| AU2002248213A1 (en) | Markers for disease susceptibility and targets for therapy | |
| AU2002221099A1 (en) | Combination drugs | |
| AU2001286721A1 (en) | Human interleukin-four induced protein | |
| AU2001227084A1 (en) | N-arylhydrazide compounds and use thereof as drugs | |
| AU2001241162A1 (en) | Remedies for allergic diseases | |
| AU2003217782A1 (en) | Dna-binding polyamide drug conjugates | |
| AU2001232244A1 (en) | Drug comprising combination | |
| AU2002241758A1 (en) | Drug screening system | |
| AU2001291691A1 (en) | Drugs for incontinence | |
| AU2001280133A1 (en) | Preventives and remedies for central nervous system diseases | |
| EP1325751A4 (en) | Novel drugs for liver diseases | |
| AU2001265714A1 (en) | Marker for neurodegenerative diseases and its use for drug screening targeted against said diseases | |
| AU2001262741A1 (en) | Medicines for the prevention and treatment of neurodegenerative diseases | |
| AUPR548601A0 (en) | Pyrazolopyrazinecompound and pharmaceutical use thereof | |
| AU2001262952A1 (en) | Fullerene-based drugs targeted to bone | |
| AU2002249453A1 (en) | Enzyme and snp marker for disease | |
| AU2001228784A1 (en) | Inositol derivatives and their pharmaceutical use | |
| AU2002322247A1 (en) | Antibacterial oxazinones and methods for their use and synthesis |